Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adenovirus vector COVID-19 vaccine
- Development stage
- Approved
- Lead developer
- AstraZeneca
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Adenovirus vector COVID-19 vaccines represent a class of viral vector-based biologics designed to prevent COVID-19. These vaccines utilize a modified, non-replicating adenovirus (such as ChAdOx1, Ad26, or Ad5) as a delivery vehicle to transport the genetic code for the SARS-CoV-2 spike (S) protein into human cells. Once the genetic material is delivered, the host's cellular machinery produces the spike protein, which is then recognized by the immune system as a foreign antigen. This process stimulates a robust immune response, including the production of neutralizing antibodies and the activation of T-cells, providing protection against subsequent infection by the SARS-CoV-2 virus. Prominent examples in this category include AstraZeneca's Vaxzevria, Johnson & Johnson's Janssen COVID-19 Vaccine, the Gamaleya Institute's Sputnik V, and CanSino Biologics' Convidecia.
- Other names
- adenoviral vector COVID-19 vaccinerecombinant adenovirus COVID-19 vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on adenovirus vector COVID-19 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adenovirus vector COVID-19 vaccine.